INT-767 is a dual agonist of farnesoid X receptor (FXR)/TGR5 with an EC50 of 0.033 μM and 0.67 μM, respectively. It significantly improves serum liver enzymes, hepatic inflammation, and biliary fibrosis, while inducing bile flow and biliary HCO₃⁻ output, making it a promising tool for chronic cholangiopathy research.

INT-767 is a dual agonist of farnesoid X receptor (FXR)/TGR5 with an EC50 of 0.033 μM and 0.67 μM, respectively. It significantly improves serum liver enzymes, hepatic inflammation, and biliary fibrosis, while inducing bile flow and biliary HCO₃⁻ output, making it a promising tool for chronic cholangiopathy research.

INT-767 is a dual agonist of farnesoid X receptor (FXR)/TGR5 with an EC50 of 0.033 μM and 0.67 μM, respectively. It significantly improves serum liver enzymes, hepatic inflammation, and biliary fibrosis, while inducing bile flow and biliary HCO₃⁻ output, making it a promising tool for chronic cholangiopathy research.

VAV1 degrader-3 (MRT-6160) is an orally active molecular glue degrader of VAV1 with a DC50 of 7 nM. It suppresses immune activation, proliferation, and cytokine production, inhibiting disease progression in inflammatory and autoimmune models like encephalomyelitis (EAE) and Collagen-induced arthritis (CIA).

VAV1 degrader-3 (MRT-6160) is an orally active molecular glue degrader of VAV1 with a DC50 of 7 nM. It suppresses immune activation, proliferation, and cytokine production, inhibiting disease progression in inflammatory and autoimmune models like encephalomyelitis (EAE) and Collagen-induced arthritis (CIA).

VAV1 degrader-3 (MRT-6160) is an orally active molecular glue degrader of VAV1 with a DC50 of 7 nM. It suppresses immune activation, proliferation, and cytokine production, inhibiting disease progression in inflammatory and autoimmune models like encephalomyelitis (EAE) and Collagen-induced arthritis (CIA).

ML-SA5 is a potent agonist of TRPML1 cation channel that activates the entire endosomal TRPML1 (ML1) current in DMD myocytes with an EC50 of 285 nM and exhibit anticancer activity.

VAV1 degrader-3 (MRT-6160) is an orally active molecular glue degrader of VAV1 with a DC50 of 7 nM. It suppresses immune activation, proliferation, and cytokine production, inhibiting disease progression in inflammatory and autoimmune models like encephalomyelitis (EAE) and Collagen-induced arthritis (CIA).

ML-SA5 is a potent agonist of TRPML1 cation channel that activates the entire endosomal TRPML1 (ML1) current in DMD myocytes with an EC50 of 285 nM and exhibit anticancer activity.

ML-SA5 is a potent agonist of TRPML1 cation channel that activates the entire endosomal TRPML1 (ML1) current in DMD myocytes with an EC50 of 285 nM and exhibit anticancer activity.